TSI-inhibiting monoclonal antibody

This page covers all TSI-inhibiting monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Thyroid-stimulating immunoglobulin (TSI).

Targets

Thyroid-stimulating immunoglobulin (TSI)

Phase 3 pipeline (1)

• VRDN-003 · Viridian Therapeutics, Inc. · Endocrinology / Immunology
  VRDN-003 is a monoclonal antibody that targets and inhibits thyroid-stimulating immunoglobulin (TSI) to reduce autoimmune thyroid activation in Graves' disease.

Patent intelligence

• tsi inhibiting monoclonal antibody patent landscape — aggregated cliff calendar, attackable patents, originator estates